Summary by Futu AI
Yunbai International Limited (“Yunbai International”) announces final results for the nine months ended 31 December 2023. The Company and its subsidiaries (the “Group”) generated revenues during this period of approximately HK$578.74 million, an increase from approximately HK$452.91 million in the previous fiscal year. Gross profit increased from approximately HK$22.91 million to approximately HK$49.60 billion. Profit for the period was approximately HK$143.73 million, compared to a loss of HK$168.86 million in the previous financial year. Basic earnings per share were HK$2.11 cents, compared to basic and diluted loss per share of HK$2.51 cents in the previous fiscal year. The Group's main business is investment holdings, primarily engaged in commodity and commodity trading. During the reporting period, the Group did not pay any dividends. Yunbai International's shares are listed on the main board of the Hong Kong Stock Exchange Limited, with Yunnan Biopharmaceuticals Group as its controlling shareholder.